Keyword Analysis & Research: cyp3a4 ddi
Keyword Research: People who searched cyp3a4 ddi also searched
Search Results related to cyp3a4 ddi on Search Engine
-
A Review of CYP3A Drug-Drug Interaction Studies: …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435708/
WEBAug 30, 2021 · In DDI studies with CYP3A inducers large effects of the drugs rifampin and enzyme-inducing antiepileptic drugs (EIAEDs) such as carbamazepine, oxcarbazepine … Author: Laura Molenaar-Kuijsten, Dorieke E. M. Van Balen, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huite... DOI: 10.3389/fphar.2021.670862 Publish Year: 2021 Publication: Front Pharmacol. 2021; 12: 670862.
Author: Laura Molenaar-Kuijsten, Dorieke E. M. Van Balen, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huite...
DOI: 10.3389/fphar.2021.670862
Publish Year: 2021
Publication: Front Pharmacol. 2021; 12: 670862.
DA: 46 PA: 65 MOZ Rank: 82
-
Predicting the Drug–Drug Interaction Mediated by …
https://link.springer.com/article/10.1208/s12248-021-00659-w
FrameworkPBPK Model of KetoconazoleData Collection of VictimsIn Silico Prediction of ADME PropertiesPBPK Model of VictimsPbpk-Ddi Model and Prediction of DdisEvaluation of Predictive PerformanceIntegration of The Reported FM and in Silico FM Into The Pbpk-Ddi ModelStatic Mechanistic ModelsThe fm values mediated by CYP3A4 were reported and used for the DDI prediction for crizotinib, macitentan, panobinostat, and ruxolitinib (12–14). The victims (crizotinib, macitentan, panobinostat, and ruxolitinib) were assumed to be metabolized by CYP3A4 and other CYP enzymes. The contribution of CYP3A4 (fm) and other CYP enzymes on the metabolism ...See more on link.springer.com The fm values mediated by CYP3A4 were reported and used for the DDI prediction for crizotinib, macitentan, panobinostat, and ruxolitinib (12–14). The victims (crizotinib, macitentan, panobinostat, and ruxolitinib) were assumed to be metabolized by CYP3A4 and other CYP enzymes. The contribution of CYP3A4 (fm) and other CYP enzymes on the metabolism ...
The fm values mediated by CYP3A4 were reported and used for the DDI prediction for crizotinib, macitentan, panobinostat, and ruxolitinib (12–14). The victims (crizotinib, macitentan, panobinostat, and ruxolitinib) were assumed to be metabolized by CYP3A4 and other CYP enzymes. The contribution of CYP3A4 (fm) and other CYP enzymes on the metabolism ...
DA: 47 PA: 17 MOZ Rank: 62
-
Drug Development and Drug Interactions | Table of …
https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
WEBJun 5, 2023 · Clinical inhibitors. Table 1-1: Examples of in vitro marker reactions for CYP-mediated metabolism. a Recommend the use of two structurally unrelated CYP3A4/5 …
DA: 49 PA: 96 MOZ Rank: 96
-
A Review of CYP3A Drug-Drug Interaction Studies: …
https://pubmed.ncbi.nlm.nih.gov/34526892/
WEBAug 30, 2021 · Review. Many oral anticancer drugs are metabolized by CYP3A. Clinical drug-drug interaction (DDI) studies often only examine the effect of strong CYP3A …
DA: 75 PA: 6 MOZ Rank: 19
-
Predicting the Drug-Drug Interaction Mediated by …
https://pubmed.ncbi.nlm.nih.gov/34893925/
WEBDec 10, 2021 · Ketoconazole. The prediction of drug-drug interactions (DDIs) plays critical roles for the estimation of DDI risk caused by inhibition of CYP3A4. The aim of this …
DA: 57 PA: 82 MOZ Rank: 99
-
A Review of CYP-Mediated Drug Interactions: …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10813492/
WEBJan 12, 2024 · Consequently, there has been a growing focus on the assessment of DDI risk for CYPs. This review article provides mechanistic insights underlying CYP …
DA: 90 PA: 9 MOZ Rank: 94
-
Prediction of Drug-Drug Interactions Arising from CYP3A …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885489/
WEBAug 18, 2015 · DDI studies involving the CYP3A4 inducer rifampicin with the CYP3A4 substrates MDZ, alfentanil, alprazolam, nifedipine, simvastatin, and zolpidem were …
DA: 13 PA: 26 MOZ Rank: 70
-
Frontiers | A Review of CYP3A Drug-Drug Interaction …
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.670862/full
WEBAug 29, 2021 · Clinical drug-drug interaction (DDI) studies often only examine the effect of strong CYP3A inhibitors and inducers. The effect of moderate or weak inhibitors or …
DA: 24 PA: 78 MOZ Rank: 2
-
Recommendations for the Design of Clinical Drug–Drug …
https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/psp4.12449
WEBJun 19, 2019 · Cytochrome P450 3A (CYP3A) enzymes are often significant contributors to the clearance (CL) of drugs and therefore strong inhibitors that are selective for these enzymes are employed in clinical …
DA: 77 PA: 74 MOZ Rank: 7
-
Improved predictions of time-dependent drug-drug …
https://www.nature.com/articles/s41598-019-42051-x
WEBApr 10, 2019 · The use of F ic -adjusted drug concentrations, i.e. intracellular unbound concentrations, in DDI predictions based on time-dependent inhibition of P450 enzymes has not yet been evaluated....
DA: 78 PA: 50 MOZ Rank: 21
